Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
about
Targeting the TAM Receptors in LeukemiaSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Thymoquinone exerts potent growth-suppressive activity on leukemia through DNA hypermethylation reversal in leukemia cells.The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.FLT3 inhibitors: clinical potential in acute myeloid leukemia.A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia.Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicityEmerging therapies for acute myeloid leukemia: translating biology into the clinic.Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6.Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study
P2860
Q28078654-06A0F073-DEBC-42D0-8896-3FDC43B2C37CQ33442949-E0468EA7-475A-4F8A-BC56-A88C04601A0FQ33798412-CC3C9E37-58DE-4C59-B87E-4D1E40DDBDE2Q36865880-9676CEA6-5A9E-44D7-A30B-08192F466476Q37638749-3BA32DCA-8E7E-427D-BC31-2104BCEFA855Q37665524-C8E221F6-F474-4ECE-8684-35C03E497F33Q38675400-F67A75DC-C091-44CE-B1DB-5C10B42A7B49Q39157476-970000A2-AD95-401D-9B3B-D372EFD5A894Q39411949-5591D781-7449-41ED-BC8A-1FA1FF11E023Q40978288-034D05A0-6500-47FE-B5CA-7B8465D8A2D8Q41093141-E3BFECE5-98EE-4D09-BA46-E09744A94458Q41940444-02C36BAA-5C56-45C8-8FFF-C8B4D6276315Q41984963-379895C9-15A1-42C5-B6C0-B34259E6C0DDQ42363757-7FD756A4-6759-4C97-8BFB-7BBBDE007EADQ47142820-7E4B3638-078B-4383-B05B-AEDA5FDA92B4Q47877035-3810E3A7-0EB6-4E58-B255-25B9B73A4882Q47965108-D0B1ED9B-F9C6-4C53-86F4-AA317CE6B5EEQ49791801-730B667C-164F-4154-B358-2542DD217BE3Q54114106-44DE1755-945D-462D-81FE-BE95E1904968Q54125246-611B4D9E-B37A-47E0-8C06-903F349E0001Q54956859-AEB71048-EA68-4FC8-8CD8-01EFA574CA48Q58785754-AC57DB33-278B-45A5-AD17-6DA5165B3534
P2860
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Receptor tyrosine kinase Axl i ...... apy in acute myeloid leukemia.
@en
type
label
Receptor tyrosine kinase Axl i ...... apy in acute myeloid leukemia.
@en
prefLabel
Receptor tyrosine kinase Axl i ...... apy in acute myeloid leukemia.
@en
P2093
P2860
P356
P1433
P1476
Receptor tyrosine kinase Axl i ...... apy in acute myeloid leukemia.
@en
P2093
B Mundy-Bosse
G Marcucci
M A Caligiuri
S L Warner
S P Whitman
P2860
P2888
P304
P356
10.1038/LEU.2015.147
P577
2015-06-19T00:00:00Z
P5875
P6179
1015134080